

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

21-729

CHEMISTRY REVIEW(S)



NDA 21-729

**Abilify® Discmelt™ (aripiprazole) Orally Disintegrating
Tablets**

Otsuka Pharmaceutical Co. Ltd

Gurpreet Gill-Sangha, Ph.D.
OFFICE OF NEW DRUG AND QUALITY ASSESSMENT
(ONDQA)
Review of Chemistry, Manufacturing, and Controls



Table of Contents

Table of Contents	2
Chemistry Review Data Sheet.....	4
The Executive Summary	8
I. Recommendations	8
A. Recommendation and Conclusion on Approvability	8
B. Recommendation on Phase 4 (Post-Marketing) Commitments, Agreements, and/or Risk Management Steps, if Approvable.....	8
II. Summary of Chemistry Assessments.....	8
A. Description of the Drug Product(s) and Drug Substance(s)	8
B. Description of How the Drug Product is Intended to be Used.....	11
C. Basis for Approvability or Not-Approval Recommendation	11
III. Administrative.....	11
A. Reviewer's Signature.....	11
B. Endorsement Block.....	11
C. CC Block	11
Chemistry Assessment.....	12
LABELING.....	41
Attachment 1: EER	47
Attachment 2: EIR Dated 5/26/2004.....	51
Attachment 3: EIR from 11-9 to 12-6-2004 Inspection.....	52
Attachment 4: EIR from 11-9 to 12-6-2004 Inspection.....	55
Attachment 5: Certificate of Analysis for Commercial 10- and 15-mg batches.....	58



CHEMISTRY REVIEW



List of Tables:

Table 1: Final Updated Abilify® Discmelt™ ODT Specifications	12
Table 2: Aripiprazole ODT Excipient Blends Placed on Stress Stability	14
Table 3: Potency of Aripiprazole and Aspartame on Stress Stability and % of Degradants Formed	15
Table 4: Tablet Content Uniformity Results from PJ Batches of 10, 15, 20 and 30 mg Abilify ODT	20
Table 5: Tablet Potency Results for PJ Batches 10, 15, 20 and 30 mg Abilify ODT	20
Table 6: Compression Process Yield Specifics for PJ Batches	21
Table 7: Tablet Compression Trend Data for Aripiprazole ODT	22
Table 8: Compression Process Yield Specifics for Long term Stability Batches of Aripiprazole ODT Using Tablet Press	23
Table 9: Compression Process Yield Specifics for Process Justification (PJ) Batches of Aripiprazole ODT Using Tablet Press	24
Table 10: Compression Rejection and Yield Specifics for Validation Batches of 10- and 15-mg Aripiprazole ODT Using Tablet Press	25
Table 11: Compression Process Yield Specifics for Post-Validation Commercial Batches of 15-mg Aripiprazole ODT using Tablet Press	26
Table 12: Tablet Compression Trend Data for Aripiprazole ODT Updated	27
Table 13: Compression Process Yield Specifics for Commercial Batches of 10-mg Aripiprazole ODT using the Tablet Press	28
Table 14: Test Results for Batch #2H56081 for 10-mg Aripiprazole ODT	29
Table 15: Sampling Plan for Tablet Compression of Aripiprazole ODT Manufactured at Mayaguez, Puerto Rico	30
Table 16: Sampling Plan for Tablet Compression Using Tablet Press	31
Table 17: Length of Time Taken for Tablet Compression of PJ Batches	31
Table 18: Disintegration Data for Aripiprazole ODT Process Justification Batches Using USP Disintegration test <701>	33
Table 19: Disintegration Data for Aripiprazole ODT LTSS Samples Stored Using the USP <701>	33
Table 20: Disintegration Data for Aripiprazole ODT Using USP<701> Disintegration Test	34
Table 21: Shipping Study on Abilify ODT from Manufacturing Facility to Packaging Site	35
Table 22: Summary of Analytical Tests for Pre- and Post-Shipping Study	36
Table 23: Comparison Data for Compression Events from Validation and Commercial Batches of Aripiprazole ODT	41



Chemistry Review Data Sheet

1. NDA 21-729
2. REVIEW #: 3
3. REVIEW DATE: June 7, 2006
4. REVIEWER: Gurpreet Gill-Sangha, Ph.D.
5. PREVIOUS DOCUMENTS: None

<u>Previous Documents</u>	<u>Document Date</u>
Original NDA submission	December 22, 2003
Amendment C	January 13, 2004
Amendment BC	March 31, 2004
Amendment BC	July 8, 2004
Amendment BC	August 4, 2004
Amendment BC	August 20, 2004
Chemistry review #1	October 15, 2004
Chemistry review #2	October 29, 2004
Approvable (AE) Letter	October 22, 2004

6. SUBMISSION(S) BEING REVIEWED:

<u>Submission(s) Reviewed</u>	<u>Document Date</u>
Amendment C	October 28, 2004
Amendment AZ	December 12, 2005
Amendment BZ	April 13, 2006
Amendment BL	May 12, 2006
Amendment (by email)	May 15, 2006
Amendment (by email)	June 1, 2006
Amendment (by email)	June 6, 2006

7. NAME & ADDRESS OF APPLICANT:

Name:	Otsuka Pharmaceutical Co., Ltd.
Address:	2-9 Kanda Tsukasa-cho Chiyoda-ku Tokyo, 101-8535, Japan
Representative*:	Kusuma Mallikaarjun, Ph.D., Senior Director, Regulatory Affairs/Abilify
Telephone:	(301) 990-0030

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.